<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02787317</url>
  </required_header>
  <id_info>
    <org_study_id>ChinaPLA general hospital</org_study_id>
    <nct_id>NCT02787317</nct_id>
  </id_info>
  <brief_title>Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI</brief_title>
  <official_title>Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prolonging infusions may decrease myocardial damage associated with bivalirudin use during
      primary PCI. The investigators hypothesized that continuing the bivalirudin infusion
      commenced during the procedure at the PCI recommended dose for 4 hours would prevent
      myocardial damage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bivalirudin is widely used as an anticoagulant during percutaneous coronary intervention
      (PCI) for coronary heart disease. Prolonging infusions may decrease myocardial damage
      associated with bivalirudin use during primary PCI . However, whether prolonging infusions of
      bivalirudin could prevent ischemic complications is unknown. The investigators examined the
      effects of prolonged drug infusion after elective PCI. The investigators hypothesized that
      continuing the bivalirudin infusion commenced during the procedure at the PCI recommended
      dose for 4 hours would prevent myocardial damage.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>creatine kinase-MB increase</measure>
    <time_frame>up to postprocedural 72 hours</time_frame>
    <description>creatine kinase-MB increase &gt;3 times upper limit of normal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bleeding（BARC class）</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>including BARC class 2-5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major adverse cardiac or cerebral events</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>a composite of all cause death, reinfarction, target vessel revascularization or stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net Adverse Clinical Events</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>a composite of all cause death, any myocardial infarction, any target vessel revascularization, stroke or any bleeding</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1770</enrollment>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For the heparin group, a bolus dose of 100 U/kg was administered according to current guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>not prolong infusion Bivalirudin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bivalirudin was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>prolong infusion bivalirudin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bivalirudin was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and prolong for 4 hours after procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bivalirudin</intervention_name>
    <description>Bivalirudin is an alternative to heparin in patients undergoing percutaneous coronary intervention.</description>
    <arm_group_label>not prolong infusion Bivalirudin</arm_group_label>
    <arm_group_label>prolong infusion bivalirudin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>Heparin is used in patients undergoing percutaneous coronary intervention.</description>
    <arm_group_label>heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 to 80 years with stable ischemic heart disease in whom PCI was
             required.

        Exclusion Criteria:

          -  cardiogenic shock;

          -  thrombolytic therapy administered before randomization or any anticoagulant
             administered within 48 hours of randomization;

          -  active or recent major bleeding or bleeding predisposition;

          -  major surgery within 1 month;

          -  clinical syndrome suspicious for aortic dissection, pericarditis, or endocarditis;

          -  blood pressure higher than 180/110 mm Hg;

          -  known hemoglobin less than 10 g/dL, platelet count less than 100 × 109/L,
             aminotransferase level greater than 3 × the upper limit of normal, or creatinine
             clearance less than 30 mL/min;

          -  history of heparin-induced thrombocytopenia;

          -  allergy to any of the study drugs or devices;

          -  pregnancy or lactation;

          -  any condition making PCI unsuitable or that might interfere with study adherence; and

          -  patient unwilling or unable to provide written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yundai chen, doctor</last_name>
    <phone>+08613581886786</phone>
    <email>dingyutinkle@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ChinaPLAGH</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>1000853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ChinaPLAGH</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>yundai chen</last_name>
      <phone>08601055499309</phone>
      <email>dingyutinkle@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, Chen S, Jiang T, Yang P, Chen J, Jiang D, Jing Q, Liang Z, Liu H, Zhao X, Li J, Li Y, Xu B, Stone GW; BRIGHT Investigators. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA. 2015 Apr 7;313(13):1336-46. doi: 10.1001/jama.2015.2323.</citation>
    <PMID>25775052</PMID>
  </reference>
  <results_reference>
    <citation>Cortese B, Picchi A, Micheli A, Ebert AG, Parri F, Severi S, Limbruno U. Comparison of prolonged bivalirudin infusion versus intraprocedural in preventing myocardial damage after percutaneous coronary intervention in patients with angina pectoris. Am J Cardiol. 2009 Oct 15;104(8):1063-8. doi: 10.1016/j.amjcard.2009.06.005.</citation>
    <PMID>19801025</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>May 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <last_update_submitted>May 31, 2016</last_update_submitted>
  <last_update_submitted_qc>May 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Yun Dai Chen</investigator_full_name>
    <investigator_title>Chinese PLA General Hospital</investigator_title>
  </responsible_party>
  <keyword>bivalirudin</keyword>
  <keyword>myocardial injure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Hirudins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

